In Reply We appreciate Dr Boffa’s comments regarding our article.1 His Letter to the Editor has raised what we believe to be an important question regarding how we view success of treatment in the advanced lung cancer setting. Several articles and more recent trends have established the changing metrics being used in non–small cell lung cancer (NSCLC) clinical trials—from overall survival to progression-free survival, durability of response, and objective response rate.2,3 We believe that this shift in outcomes in clinical trials is about accepting that survival improvements in advanced-stage lung cancer are multifactorial and more difficult to achieve, and ultimately distancing us mentally from the concept of cure and shifting to a different perspective with respect to metastatic disease.